Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD of Direclidine in Healthy Adults
NCT03244228Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of direclidine in Alzheimer's disease (AD) (5 arms), sponsored by Nxera Pharma. Primary endpoints: Treatment emergent adverse events, Physical examinations and 4 more. Started Aug 2017; status: completed.
02
Drugs
direclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03244228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244228.